ClinicalTrials.gg
CompletedNCT03424122Updated Aug 21, 2025

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

A Phase 1 interventional study of Parsaclisib and Rituximab in B-cell Lymphoma, sponsored by Incyte Corporation. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 398 studies in Lymphoma, B-Cell with a site in United States — 90 open to participants now, 156 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
146th of 380
50 · median 37
Started
2018
with 18 others
Phase 1
161 of 398
34 open now
Registered
184th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 146th largest by enrollment of the 380 interventional ones that give a count, is one of 19 that started in 2018, is one of 161 in phase 1, and was the 184th registered.

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

90 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.

03

Conditions studied

  • B-cell Lymphoma

Keywords

  • Diffuse large B-cell lymphoma (DLBCL)
  • follicular lymphoma (FL)
  • marginal zone lymphoma (MZL)
  • mantle cell lymphoma (MCL)
  • phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, aged 18 years or older on the day of signing the Form (ICF).
  • confirmed indolent/aggressive DLBCL, FL, MZL, or MCL.
  • Participants with DLBCL, MZL or MCL must have received at least 1 with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen.
  • Participants with FL must have received at least 2 prior lines of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen.
  • Ineligible for stem cell transplant.
  • Participants with DLBCL must have failed or refused stem cell transplantation or failed first-line salvage therapy if ineligible for transplantation.
  • Must be willing to undergo an incisional or excisional lymph node or tissue or to provide a lymph node or tissue biopsy from the most recent available archival tissue.
  • of > 3 months.
  • (ECOG) performance status score of 0 to 2 (see Appendix D).
  • Willingness to avoid pregnancy or fathering a child.
  • Ability to comprehend and willingness to sign an ICF

Exclusion criteria

Exclusion Criteria:

  • Evidence of transformed non-Hodgkin lymphoma histologies (with the exception of FL).
  • confirmed rare non-Hodgkin B-cell subtypes.
  • History of or central nervous system lymphoma (either primary or ) or .
  • Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K inhibitor.
  • For participants to be treated with bendamustine (Treatment B), prior treatment with bendamustine (within 12 months of the start of study treatment). Participants with prior bendamustine treatment (> 12 months before the start of study treatment) are eligible if they meet the following criteria:

    • Did not discontinue because of tolerability concerns.
    • Achieved either partial response (PR) or complete response (CR) to the bendamustine regimen of at least 12 months in duration before relapse/progression.
    • Experienced progression following a regimen containing an alkylating agent.
  • For participants to be treated with ibrutinib (Treatment C), prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor.
  • stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.
  • Active following allogeneic transplant.
  • virus (HBV) or virus (HCV) infection.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Treatment A

    Parsaclisib + Rituximab

    Drug: Parsaclisib · Drug: Rituximab

  • Experimental
    Treatment B

    Parsaclisib + Bendamustine + Rituximab

    Drug: Parsaclisib · Drug: Rituximab · Drug: Bendamustine

  • Experimental
    Treatment C

    Parsaclisib + Ibrutinib

    Drug: Parsaclisib · Drug: Ibrutinib

Interventions

  • Parsaclisib administered orally once daily for 8 weeks followed by once weekly.

    Also known as: INCB050465

  • Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.

    Also known as: Rituxan

  • Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.

    Also known as: Treanda, Bendeka

  • Ibrutinib administered orally once daily.

    Also known as: Imbruvica

06

What researchers measure

Primary outcomes

  1. Number of treatment-emergent adverse events (TEAEs)

    A TEAE is any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment.

    Time frame: Up to approximately 12 months.

Secondary outcomes

  1. Apparent clearance of parsaclisibin combination with rituximab, bendamustine and rituximab, or ibrutinib

    Measured to assess the plasma pharmacokinetic profile of parsaclisib in combination with rituximab, bendamustine and rituximab, and ibrutinib.

    Time frame: Up to approximately 1 month.

  2. Apparent volume of distribution of parsaclisib in combination with rituximab, bendamustine and rituximab, or ibrutinib

    Measured to assess the plasma pharmacokinetic profile of parsaclisib in combination with rituximab, bendamustine and rituximab, and ibrutinib.

    Time frame: Up to approximately 1 month.

07

Study locations

21 sites
  • University of Arizona Cancer Center - Out Pt.
    Tucson, Arizona 85719, United States
  • Indiana Blood and Marrow Transplantation
    Indianapolis, Indiana 46237, United States
  • Comprehensive Cancer Center of Nevada
    Las Vegas, Nevada 89169, United States
  • Texas Oncology
    Austin, Texas 78705, United States
  • Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Smith Clinic
    Houston, Texas 77054, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas 78217, United States
  • Texas Oncology San Antonio
    San Antonio, Texas 78240, United States
  • Asst Spedali Civili Di Brescia
    Brescia, 25123, Italy
  • Azienda Ospedaliera San Gerardo Di Monza
    Monza, 20835, Italy
  • Azienda Ospedaliera Universitaria Pisana
    Pisa, 56126, Italy
  • Ospedale Delle Croci - Ematologia Ravenna
    Ravenna, 48121, Italy
  • Hospital Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hospital General Universitari Vall D Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic I Provincial
    Barcelona, 08036, Spain
  • Fundacion Jimenez Diaz University Hospital
    Madrid, 28040, Spain
  • Hospital Universitario Hm Sanchinarro
    Madrid, 28050, Spain
  • Hospital Clinico Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
  • Hospital Universitario Y Politecnic La Fe
    Valencia, 46026, Spain
08

References and documents

Publications

  • Sancho JM, Abrisqueta P, Kumar A, Cordoba R, Tani M, Langmuir P, Rappold E, Liu T, Lopez-Guillermo A. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL-112). Leuk Lymphoma. 2024 Jul;65(7):911-921. doi: 10.1080/10428194.2024.2331626. Epub 2024 Apr 10. PubMed 38598516 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jun 2022, 47 months.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 47 months is close to that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Feb 6, 2018
StartActual
Jul 2, 2018
Primary completionActual
Jun 27, 2022
CompletionActual
Jun 27, 2022
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03424122
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 6, 2018
Start date
Jul 2, 2018
Primary completion
Jun 27, 2022
Completion
Jun 27, 2022
Last update
Aug 21, 2025

Study contacts

Peter Langmuir, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion